MNG932
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.417
- HYPOXIA+0.406
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.361
- UNFOLDED_PROTEIN_RESPONSE+0.358
- MYC_TARGETS_V2+0.333
- MTORC1_SIGNALING+0.322
- P53_PATHWAY+0.315
- UV_RESPONSE_UP+0.303
- IL6_JAK_STAT3_SIGNALING+0.302
- INFLAMMATORY_RESPONSE+0.275
Top 10 suppressed
- E2F_TARGETS-0.261
- PANCREAS_BETA_CELLS-0.224
- OXIDATIVE_PHOSPHORYLATION-0.177
- FATTY_ACID_METABOLISM-0.134
- G2M_CHECKPOINT-0.132
- ANGIOGENESIS-0.106
- KRAS_SIGNALING_DN-0.105
- MYOGENESIS-0.094
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.073
- ALLOGRAFT_REJECTION-0.059
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR820209 | GTEX | — | 0.777 |
| 2 | SRR1331579 | GTEX | — | 0.776 |
| 3 | SRR1466975 | GTEX | — | 0.775 |
| 4 | MNG319 | — | — | 0.770 |
| 5 | SRR1410783 | GTEX | — | 0.759 |
| 6 | MNG20 | — | — | 0.758 |
| 7 | MNG902 | — | — | 0.749 |
| 8 | MNG234 | — | — | 0.743 |
| 9 | 3E605854-CC65-4951-8EDB-235FD21FD71F | — | — | 0.740 |
| 10 | A235537D-BF50-4796-B01A-FAD83EFDAD25 | — | — | 0.736 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.417 | Inavolisib | — uncovered |
| HYPOXIA | 0.406 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.361 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.358 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.333 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.322 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.315 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.303 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.302 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.275 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.257 | Inavolisib | — uncovered |
| COAGULATION | 0.252 | Binimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.246 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.242 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.203 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.196 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.183 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.176 | Inavolisib | — uncovered |
| APOPTOSIS | 0.175 | Idelalisib | — uncovered |